Indications
Therapeutic Asset Ratings
3,272 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Plerixafor
Plasma Cell Leukemia
National Cancer Institute (NCI)
P2
CCC
(51)
Recombinant Human Granulocyte Colony-Stimulating Factor
Plasma Cell Leukemia
National Cancer Institute (NCI)
P2
CCC
(51)
Recombinant Human Hyaluronidase
Plasma Cell Leukemia
National Cancer Institute (NCI)
P2
CCC
(51)
Relatlimab
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Relatlimab
Glioma
National Cancer Institute (NCI)
P2
CCC
(51)
Sapanisertib
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Sapanisertib
Glioma
National Cancer Institute (NCI)
P2
CCC
(51)
Selumetinib
Metastatic Malignant Neoplasm
National Cancer Institute (NCI)
P2
CCC
(51)
Sotorasib
Metastatic Malignant Neoplasm
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Lymphoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Cervical Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Colon Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Endometrial Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Carcinoma Of Esophagus
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Gastric Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Head And Neck Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Hematopoietic And Lymphoid Cell Neoplasm
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Renal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Hepatocellular Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Lung Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Uterine Corpus Cancer
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Uterine Cancer
National Cancer Institute (NCI)
P2
CCC
(51)
Taselisib
Ovarian Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Showing 2326 to 2350 of 3,272 assets
Previous
Page 94 of 131
Next